MNPR early signalMNPR is @0.80 right now. Volume is an alpha, even though it looks like nothing, but it is coming in. Price is for sure showing optimism. Let's see what it brings.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.30 USD
−8.40 M USD
0.00 USD
2.01 M
About Monopar Therapeutics Inc.
Sector
Industry
CEO
Chandler Drew Robinson
Website
Headquarters
Wilmette
Founded
2014
FIGI
BBG00J7K8D90
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of MNPR is 16.88 USD — it has increased by 7.31% in the past 24 hours. Watch Monopar Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Monopar Therapeutics Inc. stocks are traded under the ticker MNPR.
MNPR stock has risen by 17.30% compared to the previous week, the month change is a 219.70% rise, over the last year Monopar Therapeutics Inc. has showed a 691.00% increase.
We've gathered analysts' opinions on Monopar Therapeutics Inc. future price: according to them, MNPR price has a max estimate of 50.00 USD and a min estimate of 9.00 USD. Watch MNPR chart and read a more detailed Monopar Therapeutics Inc. stock forecast: see what analysts think of Monopar Therapeutics Inc. and suggest that you do with its stocks.
MNPR reached its all-time high on Dec 20, 2019 with the price of 240.00 USD, and its all-time low was 1.37 USD and was reached on Nov 27, 2023. View more price dynamics on MNPR chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MNPR stock is 14.77% volatile and has beta coefficient of 2.25. Track Monopar Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is Monopar Therapeutics Inc. there?
Today Monopar Therapeutics Inc. has the market capitalization of 86.81 M, it has decreased by −34.38% over the last week.
Yes, you can track Monopar Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
Monopar Therapeutics Inc. is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
MNPR net income for the last quarter is −1.30 M USD, while the quarter before that showed −1.72 M USD of net income which accounts for 23.96% change. Track more Monopar Therapeutics Inc. financial stats to get the full picture.
No, MNPR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 10, 2024, the company has 10.00 employees. See our rating of the largest employees — is Monopar Therapeutics Inc. on this list?
Like other stocks, MNPR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Monopar Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Monopar Therapeutics Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Monopar Therapeutics Inc. stock shows the strong buy signal. See more of Monopar Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.